N+1 Singer Reiterates “corporate” Rating for ReNeuron Group Plc (RENE)

ReNeuron Group Plc (LON:RENE)‘s stock had its “corporate” rating reaffirmed by stock analysts at N+1 Singer in a research note issued on Tuesday.

TRADEMARK VIOLATION WARNING: This piece was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.com-unik.info/2017/11/02/n1-singer-reiterates-corporate-rating-for-reneuron-group-plc-rene.html.

About ReNeuron Group Plc

ReNeuron Group plc is a clinical-stage company. The Company, through its subsidiaries, is engaged in researching and developing cell-based therapies. The Company’s products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP).

What are top analysts saying about ReNeuron Group Plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ReNeuron Group Plc and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit